HungaryHungary

Promoting Hungarian R&D

05.02.2004

In order to facilitate the participation of the region's experts and institutions in the 6th EU RTD Framework Programme (FP6) projects, the Hungarian Science and Technology Foundation (HSTF) was again appointed to work as the liaison office for the Central Hungary Region and Budapest. The foundation became co-ordinator or partner in 13 FP6 projects that were accepted for contract negotiation by the EU in different thematic priorities, but mostly in the area of life sciences. The office is the coordinator of a support action in the area of food quality and safety with 26 partners.
Apart from serving as the liaison office in FP5 for the areas “Environment” and “Quality of Life” for the Central Hungary region HSTF participated in seven projects, e.g. it was a partner in two “Economic and Technological Intelligence (ETI)” projects in “Quality of Life”: “Partners for Life - The European life sciences network for SMEs” and “Fellows for Industry - a new European initiative for cooperation of academia and industry”.
Project Management for EU FP6
Although the foundation is involved more in the food and environment projects of biotechnology, it has widescale relationship in every field of science. HSTF provides assistance in establishing contacts between Hungarian and foreign researchers and research institutes. The office has an advisory service and provides assistance in proposal preparation and project management for the EU framework programmes and other EU and national possibilities.
Established by the Hungarian Minister for Foreign Affairs in 1994, the HSTF is a non-profit public foundation. Its mission is to develop the international relations of the Hungarian R&D community, to participate in Hungary's EU integration efforts by promoting activities in the field of science and technology and to facilitate the access of interested Hungarian parties to European Union R&D funding. The office has developed many contacts with scientists, research institutions, universities, enterprises, multiplier organisations and governmental agencies in Hungary, e.g. the Hungarian National Contact Points, and abroad as well.
Contact
Szilvia Szántó
Hungarian Science and Technology Foundation
eMail: szilvia.szanto@tetalap.hu, www.tetalap.hu,
Tel.: +36-1-214-7714, Fax: +36-1-214-7712

HungaryHungary

05.03.2012

It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner...

HungaryHungary

09.08.2011

Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Bio­tech sro to provide the Hungarian firm’s drug transporter assays to its customers in the bio­pharmaceutical...

HungaryHungary

09.08.2011

Budapest/Kraków – In July, illegally planted genetically modified crops made headlines in Hungary, where GMO acreage is banned. Up to 0.1% GMO maize products from Monsanto and Pioneer were discovered at four sites (near...

HungaryHungary

04.04.2011

Budapest – Hungarian vaccine developer Genetic Immunity Kft. (GI) has secured a cash injection of US$25m by signing an agreement with the Budapest-based technology commercialisation company Power of the Dream Ventures, Inc. The...

HungaryHungary

06.02.2011

Budapest/Tokyo – Hungary’s largest drugmaker Gedeon Richter Nyrt. has secured access to the Japanese market for its biosimilar pipeline. In mid-December, Richter CEO Erik Bogsch announced his company had signed a long-term...

HungaryHungary

03.11.2010

Budapest – Richter Group has bagged Swiss gynecology and infertility specialist Preg­Lem Holding SA in a 100 % equity stake worth up to EUR 359m. Hungary’s largest drugmaker expects PregLem’s lead candi­date Esmya as...

HungaryHungary

16.09.2010

Budapest – Hungary’s largest drugmaker Gedeon Richter Ltd. and US partner Forest Laboratory said that a Phase II clinical trial of their orally active drug cariprazine (RGH-188) for bipolar depression produced no “statistically...

HungaryHungary

01.07.2010

Budapest – New results from researchers at the Department of Pathology and Experimental Cancer Research in Budapest suggest that expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) on the surface of chronic...

HungaryHungary

01.02.2010

Budapest – ChemAxon, a specialist for chemical informatics software for the life sciences industry, has entered into an agreement with Pfizer. Under the terms of the agreement, Chemaxon will provide its Markush searching and...

Displaying results 1 to 10 out of 89

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-hungary/article/promoting-hungarian-rd.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR300.0%
  • SANTHERA (CH)69.30 CHF103.8%
  • ADDEX (CH)4.07 CHF82.5%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • HYBRIGENICS (F)1.72 EUR-34.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)69.30 CHF3453.8%
  • GW PHARMACEUTICALS (UK)438.00 GBP800.9%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.6%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.8%

No liability assumed, Date: 23.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events